ReviewBritish journal of cancer2025
UK guidelines for the management of bone sarcomas.
Review in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Minimal residual disease and relapse surveillance in osteosarcoma: an action-linked framework integrating liquid biopsy and imaging biomarkers.Journal of bone oncology · 2026Review
- Pulsed electromagnetic fields induce ferroptosis in osteosarcoma cells and promote osteogenic differentiation.Journal of bone oncology · 2026Article
- High-Grade Chondrosarcoma Involving the Xiphoid Process and Lower Sternum-The Continuing Role of Extended Open Chest Wall Surgery in the Era of Minimally Invasive Thoracic Surgery: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma.Cancer medicine · 2026Article
- [Should the surgical treatment of primary malignant bone tumors only take place in high-volume centers?]Orthopadie (Heidelberg, Germany) · 2026Review
- Pulmonary metastasectomy and response-adapted preoperative surveillance in resectable metastatic osteosarcoma: a single-center retrospective cohort study with long-term follow-up.Translational lung cancer research · 2026Article
- Single-cell fixed RNA profiling of the osteosarcoma clinical Spectrum identifies ADAMTS12 and RNASE1 as key drivers of the metastatic niche.Journal of bone oncology · 2026Article
- Development and validation of a SEER-based auxiliary nomogram for clinical features associated with pulmonary metastasis status in pediatric osteosarcoma.Translational pediatrics · 2026Article
- Application of a deep learning method based on CBCT panoramic reconstruction images for differentiating operationally defined cystic and neoplastic jaw lesions from osteomyelitis: a single-center retrospective study.Scientific reports · 2026Article
- Observational
- Clinical Presentation and Tumour Burden in Head and Neck Sarcomas: Implications for Early Diagnosis and Referral.Cancers · 2026Article
- Dual-Responsive Micelles Co-delivering All-Trans Retinoic Acid and Paclitaxel for Enhanced Eradication of Osteosarcoma Stem Cells.ACS omega · 2026Article
- Imaging findings and complications after curettage of atypical cartilaginous tumors in long bones: a retrospective single-center cohort study.Skeletal radiology · 2026Article
- Epidemiology and Prognosis of Patients With Osteosarcoma at Different Primary Sites: A SEER Population-Based Study.Cancer reports (Hoboken, N.J.) · 2026Article
- HPV-positive cancers at uncommon sites: a narrative review.Oncology reviews · 2026Review
- Ferroptosis in orthopedic implant integration after oncologic surgery.Frontiers in oncology · 2026Review
- Actionable diagnostic delay in primary malignant bone tumors: a trigger-to-action framework for first-contact clinicians.Frontiers in oncology · 2026Review
- Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.Exploration of targeted anti-tumor therapy · 2026Review
- Case Report: Primary giant chondrosarcoma of the manubrium sterni.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This document is an update of the British Sarcoma Group guidelines (2016) and provides a reference standard for the clinical care of UK patients with primary malignant bone tumours (PMBT) and giant cell tumours (GCTB) of bone. The guidelines recommend treatments that are effective and should be available in the UK, and support decisions about management and service delivery. The document represents a consensus amongst British Sarcoma Group members in 2024. Key recommendations are that bone pain, or a palpable mass should always lead to further investigation and that patients with clinical or radiological findings suggestive of a primary bone tumour at any anatomic site should be referred to a specialist centre and managed by an accredited bone sarcoma multidisciplinary team. Treatment recommendations are provided for the major tumour types and for localised, metastatic and recurrent disease. Follow-up schedules are suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.